AIM: The primary aim of this investigation was to examine genotype and clinical phenotype differences in individuals with juvenile neuronal ceroid lipofuscinosis (JNCL) who were homozygous for a common disease-causing deletion or compound heterozygous. The secondary aim was to cross-validate the Child Behavior Checklist (CBCL) and the Unified Batten Disease Rating Scale (UBDRS), a disease-specific JNCL rating scale. METHOD: Sixty individuals (28 males, 32 females; mean age 15y 1mo, SD 4y 9mo, range 5y 8mo--31y 1mo) with JNCL completed the UBDRS. RESULTS: No significant genotype and clinical phenotype differences were identified when comparing individuals homozygous for the deletion with a heterogeneous group of compound heterozygous individuals. There were significant correlations among related behaviour items and scales on the CBCL and UBDRS (Spearman's rho ranging from 0.39 [p<0.05] to 0.72 [p<0.01]). Behaviour and physical function ratings were uncorrelated, supporting divergent validity of these two constructs in JNCL. INTERPRETATION: Previous reports of genotype and clinical phenotype differences were unsupported in this investigation, which did not find differences between individuals homozygous or heterozygous for the CLN3 deletion. The CBCL, an already validated measure of behaviour problems, appears valid for use in JNCL and cross-validates well with the UBDRS.
AIM: The primary aim of this investigation was to examine genotype and clinical phenotype differences in individuals with juvenile neuronal ceroid lipofuscinosis (JNCL) who were homozygous for a common disease-causing deletion or compound heterozygous. The secondary aim was to cross-validate the Child Behavior Checklist (CBCL) and the Unified Batten Disease Rating Scale (UBDRS), a disease-specific JNCL rating scale. METHOD: Sixty individuals (28 males, 32 females; mean age 15y 1mo, SD 4y 9mo, range 5y 8mo--31y 1mo) with JNCL completed the UBDRS. RESULTS: No significant genotype and clinical phenotype differences were identified when comparing individuals homozygous for the deletion with a heterogeneous group of compound heterozygous individuals. There were significant correlations among related behaviour items and scales on the CBCL and UBDRS (Spearman's rho ranging from 0.39 [p<0.05] to 0.72 [p<0.01]). Behaviour and physical function ratings were uncorrelated, supporting divergent validity of these two constructs in JNCL. INTERPRETATION: Previous reports of genotype and clinical phenotype differences were unsupported in this investigation, which did not find differences between individuals homozygous or heterozygous for the CLN3 deletion. The CBCL, an already validated measure of behaviour problems, appears valid for use in JNCL and cross-validates well with the UBDRS.
Authors: L Lauronen; P B Munroe; I Järvelä; T Autti; H M Mitchison; A M O'Rawe; R M Gardiner; S E Mole; J Puranen; A M Häkkinen; E Kirveskari; P Santavuori Journal: Neurology Date: 1999-01-15 Impact factor: 9.910
Authors: F J Marshall; E A de Blieck; J W Mink; L Dure; H Adams; S Messing; P G Rothberg; E Levy; T McDonough; J DeYoung; M Wang; D Ramirez-Montealegre; J M Kwon; D A Pearce Journal: Neurology Date: 2005-07-26 Impact factor: 9.910
Authors: Heather R Adams; Jennifer Kwon; Frederick J Marshall; Elisabeth A de Blieck; David A Pearce; Jonathan W Mink Journal: J Child Neurol Date: 2007-05 Impact factor: 1.987
Authors: Jennifer Cialone; Heather Adams; Erika F Augustine; Frederick J Marshall; Jennifer M Kwon; Nicole Newhouse; Amy Vierhile; Erika Levy; Leon S Dure; Katherine R Rose; Denia Ramirez-Montealegre; Elisabeth A de Blieck; Jonathan W Mink Journal: J Inherit Metab Dis Date: 2011-12-14 Impact factor: 4.982
Authors: Jonathan W Mink; Erika F Augustine; Heather R Adams; Frederick J Marshall; Jennifer M Kwon Journal: J Child Neurol Date: 2013-07-09 Impact factor: 1.987
Authors: Elisabeth A de Blieck; Erika F Augustine; Frederick J Marshall; Heather Adams; Jennifer Cialone; Leon Dure; Jennifer M Kwon; Nicole Newhouse; Katherine Rose; Paul G Rothberg; Amy Vierhile; Jonathan W Mink Journal: Contemp Clin Trials Date: 2013-04-26 Impact factor: 2.226
Authors: Anne-Hélène Lebrun; Parisa Moll-Khosrawi; Sandra Pohl; Georgia Makrypidi; Stephan Storch; Dirk Kilian; Thomas Streichert; Benjamin Otto; Sara E Mole; Kurt Ullrich; Susan Cotman; Alfried Kohlschütter; Thomas Braulke; Angela Schulz Journal: Mol Med Date: 2011-08-18 Impact factor: 6.354
Authors: R Kohan; I A Cismondi; A M Oller-Ramirez; N Guelbert; Tapia V Anzolini; G Alonso; S E Mole; Dodelson R de Kremer; Noher I de Halac Journal: Curr Pharm Biotechnol Date: 2011-06 Impact factor: 2.837
Authors: Erika F Augustine; Heather R Adams; Christopher A Beck; Amy Vierhile; Jennifer Kwon; Paul G Rothberg; Frederick Marshall; Robert Block; James Dolan; Jonathan W Mink Journal: Dev Med Child Neurol Date: 2014-11-11 Impact factor: 5.449